ICON Public (NASDAQ:ICLR) Given New $160.00 Price Target at Robert W. Baird

ICON Public (NASDAQ:ICLR - Get Free Report) had its price objective cut by investment analysts at Robert W. Baird from $192.00 to $160.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a "neutral" rating on the medical research company's stock. Robert W. Baird's price objective would suggest a potential upside of 11.87% from the company's current price.

Other research analysts have also issued research reports about the company. Truist Financial decreased their target price on ICON Public from $262.00 to $208.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Barclays restated an "equal weight" rating and set a $165.00 price target (down from $240.00) on shares of ICON Public in a research note on Thursday, April 10th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $263.00 price objective on shares of ICON Public in a research report on Wednesday, January 15th. William Blair restated an "outperform" rating on shares of ICON Public in a research note on Tuesday, January 14th. Finally, The Goldman Sachs Group lowered shares of ICON Public from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $250.00 to $200.00 in a research note on Friday, March 21st. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $215.33.

ICON Public Price Performance

Shares of NASDAQ ICLR traded up $0.06 during trading hours on Friday, hitting $143.02. 1,400,279 shares of the stock were exchanged, compared to its average volume of 980,627. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. ICON Public has a 1-year low of $133.28 and a 1-year high of $347.72. The company has a market cap of $11.55 billion, a PE ratio of 15.01, a price-to-earnings-growth ratio of 1.86 and a beta of 1.23. The company's fifty day simple moving average is $165.03 and its two-hundred day simple moving average is $194.75.

ICON Public (NASDAQ:ICLR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The medical research company reported $3.19 earnings per share for the quarter, topping analysts' consensus estimates of $3.17 by $0.02. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.03 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The firm's revenue for the quarter was down 4.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.47 earnings per share. On average, sell-side analysts predict that ICON Public will post 13.38 EPS for the current year.

Institutional Investors Weigh In On ICON Public

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ICLR. Sierra Ocean LLC purchased a new stake in ICON Public during the fourth quarter worth $29,000. Park Place Capital Corp grew its stake in ICON Public by 281.4% in the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company's stock valued at $47,000 after acquiring an additional 166 shares during the period. Private Trust Co. NA raised its position in shares of ICON Public by 48.8% during the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company's stock worth $52,000 after purchasing an additional 82 shares during the last quarter. NBC Securities Inc. acquired a new stake in ICON Public during the 1st quarter worth $59,000. Finally, GAMMA Investing LLC grew its holdings in ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company's stock valued at $91,000 after buying an additional 169 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.